Cisplatin-induced renal effects and thromboxane A(2) receptor blockade

The aim of this study was to evaluate the renal protective effect of Linotroban, a thromboxane A(2) receptor antagonist, in 25 patients with malignant rumours scheduled for cisplatin therapy. Cisplatin was administered Ih after the start of a 24-h continuous infusion of linotroban or placebo. Glomerular filtration rate and effective renal plasma flow were measured. Infusions of cisplatin decreased glomerular filtration rate by 17 +/- 25 mt min(-1) (P = 0.049 vs. baseline) and effective renal plasma flow by 94 +/- 150 mt min(-1) (P = 0.049 vs. baseline) in the placebo group. In the linotroban group a decrease in glomerular filtration rate by 11 +/- 18 mL min(-1) (P = 0.050 vs. baseline) and in effective renal plasma flow by 26 +/- 63 mt min(-1) (P = 0.2 vs. baseline) was noted. However, no difference was noted between groups in response to treatment. Our findings indicate that linotroban may not be useful for prevention of cisplatin's acute nephrotoxic effects.